Equities research analysts at JPMorgan Chase & Co. upped their target price on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) from $34.00 to $45.00 in a research note issued to investors on Tuesday, American Banking and Market News reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 7.27% from the stock’s previous close.
Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded up 25.11% during mid-day trading on Tuesday, hitting $41.95. 2,578,073 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a 52-week low of $14.07 and a 52-week high of $35.80. The stock’s 50-day moving average is $27.3 and its 200-day moving average is $24.83. The company’s market cap is $782.0 million.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last announced its earnings results on Tuesday, August 6th. The company reported ($0.67) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.70) by $0.03. Analysts expect that KYTHERA Biopharmaceuticals will post $-2.97 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Cowen and Company reiterated a “buy” rating on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) in a research note to investors on Tuesday. They now have a $50.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) from $34.00 to $50.00 in a research note to investors on Tuesday. Finally, analysts at Goldman Sachs Group Inc. initiated coverage on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) in a research note to investors on Tuesday. They set a “neutral” rating and a $37.00 price target on the stock.
Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $42.80.
In other KYTHERA Biopharmaceuticals news, General Counsel Keith Klein unloaded 4,500 shares of the company’s stock on the open market in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $32.00, for a total value of $144,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.